Group revenue of $882 million, up 24% in H1 2016 and up 28% in constant currency5
Completed West-Ward Columbus acquisition, making significant progress with integration and on track to deliver cost synergies
Group core operating profit of $176 million, down 14% and down 3% in constant currency, due to a lower contribution from specific market opportunities for the Generics business compared with the first half of 2015
Group core basic earnings per share of 48.2 cents, down 32% and down 21% in constant currency
Launched 44 products and received 182 approvals, expanding and enhancing our global product portfolio
Launched 3 Bedford products in the year to-date and on track to achieve our target of 20 Bedford launches by the end of 2017
Interim dividend of 11.0 cents per share, in line with the interim dividend for H1 2015
The guidance published in the trading update on 3 August 2016 is unchanged
Continue to expect 2016 Group revenue in the range of $2.0 billion to $2.1 billion in constant currency, driven by strong growth in Injectables and Branded and the consolidation of ten months of revenue from West-Ward Columbus
